L. Komguem , P. Guilbert , M. Doublier , F. Guillemin
{"title":"紫杉烷和曲妥珠单抗新辅助化疗后HER2+乳腺癌的组织学反应研究","authors":"L. Komguem , P. Guilbert , M. Doublier , F. Guillemin","doi":"10.1016/j.gyobfe.2016.06.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response.</p></div><div><h3>Methods</h3><p>Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on <em>logiciel</em> XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test.</p></div><div><h3>Results</h3><p>The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67<!--> <!-->><!--> <!-->44%.</p></div><div><h3>Conclusion</h3><p>The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67<!--> <!-->><!--> <!-->44%.</p></div>","PeriodicalId":55077,"journal":{"name":"Gynecologie Obstetrique & Fertilite","volume":"44 7","pages":"Pages 396-402"},"PeriodicalIF":0.0000,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gyobfe.2016.06.007","citationCount":"1","resultStr":"{\"title\":\"Étude de réponse histologique du cancer du sein HER2+ après chimiothérapie néoadjuvante associant taxane et trastuzumab\",\"authors\":\"L. Komguem , P. Guilbert , M. Doublier , F. Guillemin\",\"doi\":\"10.1016/j.gyobfe.2016.06.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response.</p></div><div><h3>Methods</h3><p>Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on <em>logiciel</em> XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test.</p></div><div><h3>Results</h3><p>The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67<!--> <!-->><!--> <!-->44%.</p></div><div><h3>Conclusion</h3><p>The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67<!--> <!-->><!--> <!-->44%.</p></div>\",\"PeriodicalId\":55077,\"journal\":{\"name\":\"Gynecologie Obstetrique & Fertilite\",\"volume\":\"44 7\",\"pages\":\"Pages 396-402\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.gyobfe.2016.06.007\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecologie Obstetrique & Fertilite\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1297958916301692\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologie Obstetrique & Fertilite","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1297958916301692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Étude de réponse histologique du cancer du sein HER2+ après chimiothérapie néoadjuvante associant taxane et trastuzumab
Objectives
In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response.
Methods
Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on logiciel XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test.
Results
The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67 > 44%.
Conclusion
The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67 > 44%.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
